Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biogen is set to receive as much as $250 million in funding to develop a late-stage experimental lupus ...

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries ...